cancer cell membrane-coated for anticancer vaccination
Name: Ashley Victoria Kroll
Grad Year: 2020
Cancer vaccines have been hindered by various design roadblocks, namely multivalent antigen presentation and co-delivery of antigen and adjuvant to antigen presenting cells. The cancer cell membrane-coated nanoparticle (CCNP) is a new platform that is rationally designed to present multivalent cancer antigens and an adjuvant to dendritic cells, facilitating an anticancer immune response. The CCNP consists of three components: a PLGA nanoparticle core loaded with CpG as a potent adjuvant that is then coated with cancer cell membrane as an antigen. The formulation presents a natural and accurate representation of the cancer cell surface antigens while incorporating both adjuvant and antigen into a single carrier. This concurrent delivery to dendritic cells results in a strong and specific stimulation of the immune system. We demonstrate that our formulation improves CpG delivery to dendritic cells and can coordinate antigen presentation to T cells, culminating in an anticancer effect in a B16-F10 mouse melanoma model. This proof-of-concept work demonstrates the benefits of nanoparticulate vaccine formulations and a promising application of cell membrane-coated nanoparticles.
Industry Application Area(s)
Life Sciences/Medical Devices & Instruments